In this invited feature article, the invention of pressurized gyration in 2013 and its subsequent development into sister processes such as pressurized melt gyration, infusion gyration, and pressure‐coupled infusion gyration is elucidated. The fundamentals of these processes are discussed, elucidating how these novel methods can be used to facilitate mass production of polymeric fibers and other morphologies. The effects of the main system parameters: rotational speed and gas pressure, are discussed along with the influence of solution parameters such as viscosity and polymer chain entanglement. The effect of flow of material into the gyrator in infused gyration is also illustrated. Examples of many polymers that have been subjected to these processes are discussed and the applications of resulting products are illustrated under several different research themes such as, tissue engineering, drug delivery, diagnostics, hydrogels, filtration, and wound healing.

Organ dysfunction is a major cause of morbidity and mortality. Transplantation is typically the only definitive cure, challenged by the lack of sufficient donor organs. Tissue engineering encompasses the development of biomaterial scaffolds to support cell attachment, proliferation, and differentiation, leading to tissue regeneration. For efficient clinical translation, the forming technology utilized must be suitable for mass production. Herein, uniaxial polyhydroxyalkanoate scaffolds manufactured by pressurized gyration, a hybrid scalable spinning technique, are successfully used in bone, nerve, and cardiovascular applications. Chorioallantoic membrane and in vivo studies provided evidence of vascularization, collagen deposition, and cellular invasion for bone tissue engineering. Highly efficient axonal outgrowth was observed in dorsal root ganglion-based 3D ex vivo models. Human induced pluripotent stem cell derived cardiomyocytes exhibited a mature cardiomyocyte phenotype with optimal calcium handling. This study confirms that engineered polyhydroxyalkanoate-based gyrospun fibers provide an exciting and unique toolbox for the development of scalable scaffolds for both hard and soft tissue regeneration.

Front Cover: Pressurised gyration was invented recently to mass produce fibers using simultaneous application of pressure and rotation on polymer solutions. Since then, several novel fiber manufacturing routes such as pressurised melt, infusion and pressure‐coupled infusion gyration have evolved rapidly from this invention. These developments offer a tremendous boost to the rapid large‐scale production of different polymeric fibers and fiber products. Such developments are highlighted in article https://doi.org/10.1002/mame.201800218 by Mohan Edirisinghe and co‐workers.

Silk has attracted considerable interest for use in biomedical applications due to its high strength and promising biocompatibility. Degummed silk, consisting only of silk fibroin (SF), has been processed using various methods and can be made into films, sponges, and fibers. Pressurized gyration (PG) is capable of rapidly producing aligned fibers and offers a great amount of control over their structure and morphology. Here, SF fibers are produced for the first time using PG. The effect of varying SF concentration and applied working pressure to the gyration vessel is reported, along with the resulting effect on fiber diameter, morphology, and structural composition. Aligned microfibers are found at concentrations of 8, 10, 12 w/v%, with the lowest fiber diameters reported at 8 w/v% SF 0.3 MPa applied pressure (2.1 ± 1.3 µm). Fourier‐transform infrared spectroscopy (FTIR) confirms the existence of PG spun fibers in both random coil and β‐sheet formations.

Silk fibroin (SF) fibers are highly regarded in tissue engineering because of their outstanding biocompatibility and tunable properties. A challenge remains in overcoming the trade-off between functioning and biocompatible fibers and the use of cytotoxic, environmentally harmful organic solvents in their processing and formation. The aim of this research was to produce biocompatible SF fibers without the use of cytotoxic solvents, via pressurized gyration (PG). Aqueous SF was blended with poly(ethylene oxide) (PEO) in ratios of 80:20 (labeled SF-PEO 80:20) and 90:10 (labeled SF-PEO 90:10) and spun into fibers using PG, assisted by a range of applied pressures and heat. Pure PEO (labeled PEO-Aq) and SF solubilized in hexafluoro-isopropanol (HFIP) (labeled SF-HFIP) and aqueous SF (labeled SF-Aq) were also prepared for comparison. The resulting fibers were characterized using SEM, TGA, and FTIR. Their in vitro cell behavior was analyzed using a Live/Dead assay and cell proliferation studies with the SaOS-2 human bone osteosarcoma cell line (ATCC, HTB-85) and human fetal osteoblast cells (hFob) (ATCC, CRL-11372) in 2D culture conditions. Fibers in the micrometer range were successfully produced using SF-PEO blends, SF-HFIP, and PEO-Aq. The fiber thickness ranged from 0.71 ± 0.17 μm for fibers produced using SF-PEO 90:10 with no applied pressure to 2.10 ± 0.78 μm for fibers produced using SF-PEO 80:10 with 0.3 MPa applied pressure. FTIR confirmed the presence of SF via amide I and amide II bands in the blend fibers because of a change in structural conformation. No difference was observed in thermogravimetric properties among varying pressures and no significant difference in fiber diameters for pressures. SaOS-2 cells and hFOb cell studies demonstrated higher cell densities and greater live cells on SF-PEO blends when compared to SF-HFIP. This research demonstrates a scalable and green method of producing SF-based constructs for use in bone-tissue engineering applications.